TQB3617 / Sino Biopharm - LARVOL DELTA

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study (ASH 2025) - P1, P1/2, P2 | "Rovadicitinib in combination with TQB3617 was generally safe, well-tolerated, and showed clinical activityin pts with MF who were either JAKi-naïve or had a suboptimal response to JAKi treatment. This regimenmay represent a new treatment option for such patients with MF. A phase III study is currently beingplanned in pts with MF who had a suboptimal response to JAKi treatment."

Clinical • Combination therapy • P1/2 data • Hematological Disorders • Hematological Malignancies • Lymphoma • Myelofibrosis • CALR • HEY1 • JAK2

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study (ASH 2024) - P1, P1/2, P2 | "Rovadicitinib may be a new treatment option for those patients who failed ruxolitinib. Meanwhile, a phase Ib/II study is ongoing, aiming to assess the efficacy and safety of Rovadicitinib combined with TQB3617 (a novel oral BET inhibitor) in patients with myelofibrosis (NCT06122831)."

Clinical • P1 data • Anemia • Hematological Disorders • Infectious Disease • Myelofibrosis • Respiratory Diseases • CALR • JAK2

TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial. (PubMed, Med) - P1 | "TQB3617 showed an acceptable safety profile and promising efficacy in patients with relapsed or refractory lymphomas."

Journal • P1 data • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Varicella Zoster

TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial (ScienceDirect) - "Three patients discontinued study treatment due to TRAEs (all thrombocytopenia). The overall response rate (ORR) was 31% (12/39; complete response in 4 patients), with ORRs of 31% (5/16) in patients with Hodgkin’s lymphoma, 31% (5/16) in patients with T cell lymphoma, and 29% (2/7) in patients with B cell lymphoma."

P1 data • Hodgkin Lymphoma

First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies. (ASCO 2024) - P1, P1/2 | "TQB3617 was generally safe, well-tolerated and demonstrated encouraging efficacy in pts/w lymphoma or MF. Meanwhile, a phase Ib/II study is ongoing, aiming to assess the efficacy and safety of rovadicitinib combined with TQB3617 in pts/w MF (NCT06122831). More studies are planned."

Clinical • P1 data • Anemia • Diabetes • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Hypertriglyceridemia • Lymphoma • Myelofibrosis • Oncology • Solid Tumor • Varicella Zoster

52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING (HKEXnews) - "The board of directors...of the Sino Biopharmaceutical Limited...announced that the Group’s category 1 innovative drugs...'TQB3617 (BET inhibitor)', 'TQB3728 (IAP antagonist)', 'TQB2930 (HER2 bispecific antibody)' and others will present 52 latest research results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, covering clinical research and basic research on multiple types of cancers..."

Clinical data • Breast Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Solid Tumor

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Myelofibrosis

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov) - P1/2 | N=78 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Myelofibrosis

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1; N=38; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1; N=38; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Oncology